Effects of Nicorandil on Angina Symptoms in Patients With Coronary Slow Flow
Status:
Completed
Trial end date:
2013-06-01
Target enrollment:
Participant gender:
Summary
Slow coronary flow is an angiographically diagnosed phenomenon defined as delayed
opacification of epicardial arteries in the absence of significant arterial narrowing and
blockade. Endothelial dysfunction at the level of microarteries have been proposed as the
main pathological mechanism in this regard. Available evidence suggest that standard
anti-angina medications (e.g. nitroglycerin) that solely target large coronary trunks might
not provide adequate symptomatic relief in patients with slow coronary flow phenomenon. It is
hypothesized that anti-angina medications which exert vasodilatory effects in large coronary
arteries as well as small dividing branches might be superior to nitroglycerin in
amelioration of angina symptoms. The present randomized clinical trial was thus designed and
conducted to compare the short-term efficacy of nicorandil (a dual-acting anti-angina
medication with effects on both large and small coronary vessels) with nitroglycerin in a
group of patients with slow coronary flow presented with frequent angina episodes.